Verrica Pharmaceuticals Inc. - Common Stock (VRCA)
0.6737
+0.0037 (0.55%)
Verrica Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing innovative treatments for dermatological conditions, particularly for skin diseases like warts and other cutaneous manifestations
The company is dedicated to advancing its proprietary product candidates that utilize a unique approach to deliver targeted therapies, aiming to improve patient outcomes and enhance the quality of life for individuals suffering from these conditions. By leveraging its expertise and cutting-edge technology, Verrica is committed to addressing unmet medical needs within the dermatology space.
Verrica Pharmaceuticals shares positive preliminary results from Part 2 of its Phase 2 trial for VP-315 in treating basal cell carcinoma, showing promising tumor reduction and safety. No serious adverse events reported.
As of Dec. 20, 2023, four stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
